Hologic closes its $1.7 billion Cynosure buy
In March, Hologic (NSDQ:HOLX) closed its $1.65 billion acquisition of Cynosure Inc. (NSDQ:CYNO) and its portfolio of medical aesthetic products and devices.
Marlborough, Mass.-based Hologic paid $66 per share for a total of 17 million shares of Class A stock, representing approximately 70.6% of the company’s outstanding shares.
“We are pleased to complete our acquisition of Cynosure, and look forward to working with Michael Davin and the entire Cynosure team to achieve even greater success in the large, rapidly growing medical aesthetics market. Acquiring Cynosure, combined with divesting our blood screening business, fundamentally reshapes our business portfolio and makes us a stronger, faster-growing company,” Hologic chair, prez & CEO Steve MacMillan said in a press release.
NEXT: Integra Lifesciences looks to buy J&J’s Codman Neurosurgery unit for $1.05 billion
